<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02705677</url>
  </required_header>
  <id_info>
    <org_study_id>RDCRN # 5213</org_study_id>
    <secondary_id>U54HD061222</secondary_id>
    <nct_id>NCT02705677</nct_id>
  </id_info>
  <brief_title>Biobanking of Rett Syndrome and Related Disorders</brief_title>
  <official_title>Biobanking of Rett Syndrome and Related Disorders Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Rare Diseases (ORD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching purpose of this study is to advance understanding of the natural history of
      Rett syndrome (RTT), MECP2-duplication disorder (MECP2 Dup), RTT-related disorders including
      CDKL5, FOXG1, and individuals with MECP2 mutations who do not have RTT. Although all these
      disorders are the result of specific genetic changes, there remains broad clinical variation
      that is not entirely accounted for by known biological factors. Additionally, clinical
      investigators currently do not have any biomarkers of disease status, clinical severity, or
      responsiveness to therapeutic intervention. To address these issues, biological materials
      (DNA, RNA, plasma, cell lines) will be collected from affected individuals and in some cases
      from unaffected family members, initial evaluation performed to identify additional
      biological factors contributing to disease severity, and these materials will be stored for
      future characterization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the present time, effective treatments for RTT, MECP2 Dup, or Rett-related disorders are
      lacking. Investigators have made substantial progress in RTT over the past eleven years such
      that this study represents a narrowing of focus to mutations or duplications of the MECP2
      gene and related disorders, including those with phenotypic overlap. Understanding of RTT has
      advanced remarkably well through the Rett Syndrome Natural History Clinical Protocol (NHS)
      and correspondingly advancement in the basic science realm has moved forward with equivalent
      success. Thus, progress in clinical and basic science has led to the establishment of
      clinical trials and other translational studies that hold promise for additional clinical
      trials in future. In the process, however, investigators became aware of additional MECP2-
      and RTT-related disorders that were unknown at the time the original proposal was conceived
      and further were impressed by the substantial clinical variability in individuals with RTT
      that cannot be explained by differences in mutations alone. In fact, variability among
      individuals with identical mutations has led investigators to search for additional
      explanations. At the time of the initial application (2002), just three years after the
      identification of the gene, MECP2, as the molecular link to RTT, investigators were not aware
      of the variation in clinical disorders related to MECP2 mutations or to the related but quite
      different MECP2 Dup. Each disorder is characterized by significant neurodevelopmental
      features related either to alterations in the MECP2 gene or related to phenotypes closely
      resembling those seen in individuals with RTT. Further, the phenotypic overlap with RTT due
      to mutations in CDKL5 and FOXG1 was also unexplored. The investigators propose in this new
      study to build on the substantial progress made in understanding both classic and variant RTT
      and to add these related disorders, MECP2 Dup and the Rett-related disorders including CDKL5,
      FOXG1, and individuals with MECP2 mutations who do not have RTT. In conjunction with the
      longitudinal clinical assessment performed via the natural history component, investigators
      will systematically collect from all willing participant's blood and isolate plasma, DNA, and
      RNA. All participants in the Natural History Study will be asked to contribute samples at the
      initial visit, whereas samples will be collected repeatedly on a subset of participants in
      order to look for changes over time. In order to identify factors that distinguish between
      affected and unaffected individuals, as well as to have the potential to characterize the
      heritability and potential consequences of genetic changes in families, samples will be
      collected from unaffected family members. Additionally, on a subset of individuals chosen
      because of unique clinical features skin biopsies and/or hair follicles will be collected to
      establish cell lines. Investigators will ask all individuals providing samples to agree to
      potential future whole-genome sequencing in order to be able to potentially evaluate for
      genetic modifiers of these diseases.

      These materials will be stored at a central repository (Greenwood Genetics Laboratory). The
      main purpose of these samples is to serve as durable materials for future analyses, however,
      a set of defined analyses will be performed on all samples. For the samples collected in the
      Rett syndrome cohort, investigators will perform X-chromosome inactivation studies and
      evaluate common polymorphisms in Brain derived neurotrophic factor (BDNF) and determine the
      contribution of these known factors to disease severity. For MECP2 Dup cohort investigators
      will characterize inflammatory markers in the plasma and correlate these with clinical
      features. Also for MECP2 Dup cohort investigators will perform detailed genomic breakpoint
      and gene content analysis and correlate this with disease severity. Similar analysis of
      genomic breakpoints and gene content will be performed on people with FOXG1 Duplications.
      Finally, in a pilot study, investigators will perform metabolic profiling on people from all
      disorders and evaluate for metabolic features correlated with disease severity, and metabolic
      features common or unique between these disorders. This work will provide a durable resource
      for future analysis, extend understanding of genotype/phenotype correlations, identify other
      biological factors contributing to disease severity, as well as provide the framework for the
      development of biomarkers of disease state and severity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>X-chromosome inactivation in Rett syndrome (RTT)</measure>
    <time_frame>5 years</time_frame>
    <description>Characterize X-chromosome inactivation in RTT and correlate with clinical severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bdnf polymorphisms in RTT</measure>
    <time_frame>5 years</time_frame>
    <description>Characterize Bdnf polymorphisms in RTT and correlate with clinical severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammation markers in MECP2 duplication syndrome</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate inflammation markers in MECP2 duplication syndrome and correlate with disease severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biobanking of blood for Rett syndrome (RTT), MECP2 duplication syndrome, FOXG1, CDKL5, and MECP2 mutations not producing RTT</measure>
    <time_frame>5 years</time_frame>
    <description>Blood will be collected and stored from participants with RTT, MECP2 duplication, FOXG1, CDKL5, and MECP2 mutations without RTT to analyze factors noted in Outcomes 1-3 and in secondary outcome 5 to correlate with disease severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breakpoints and gene content of MECP2 and FOXG1 duplications</measure>
    <time_frame>5 years</time_frame>
    <description>Characterize breakpoints and gene content of MECP2 and FOXG1 duplications and correlate with disease severity</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Rett Syndrome</condition>
  <condition>MECP2 Duplication</condition>
  <condition>CDKL5</condition>
  <condition>FOXG1 Disorders</condition>
  <arm_group>
    <arm_group_label>Rett syndrome</arm_group_label>
    <description>This is a biobanking project for individuals with mutations in MECP2 or meeting diagnostic criteria for classic (typical) or variant (atypical) Rett syndrome in order to identify other genetic factors such as X-chromosome inactivation or genetic background that may explain the variations noted in these individuals, including those with the same MECP2 mutation. No interventions are anticipated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MECP2 Duplication disorder</arm_group_label>
    <description>This is a biobanking project for individuals with MECP2 duplications to understand the difference in the size of the duplication and the potential impact of other genes in the duplicated segment. No interventions are anticipated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rett-related disorders</arm_group_label>
    <description>This is a biobanking project for individuals with mutations in MECP2, CDKL5, and FOXG1 to understand the interplay of mutations in these individuals and the resultant phenotypic expression; for example, individuals with mutations in MECP2 but not meeting diagnostic criteria for Rett syndrome or individuals with mutations in CDKL5 or FOXG1 who may or may not meet diagnostic criteria for atypical Rett syndrome. No interventions are anticipated.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA and RNA from blood, plasma, hair follicles, skin biopsies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Females and males of all ages must have complete testing for MECP2, FOXG1, and CDKL5 genes
        mutations AND must meet these requirements:

        Gene positive for a sequence mutation, duplication or deletion in one of these 3 genes.

        OR Meet consensus criteria for Rett syndrome (typical or atypical)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals of both genders and of all ages, with RTT, MECP2 Dup, and, RTT-related
             disorders including those with mutations or deletions in CDKL5 and FOXG1 genes, or
             those with RTT (atypical or typical) who are mutation negative. Additionally,
             unaffected family members of those people who meet the disease specific criteria
             stated will eligible.

        Exclusion Criteria:

          -  Individuals who do not meet the above criteria will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey L Neul, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter E Kaufmann, MD</last_name>
    <role>Study Director</role>
    <affiliation>Greenwood Genetic Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alan K Percy, MD</last_name>
    <phone>2059964927</phone>
    <email>apercy@uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane B Lane, RN, BSN</last_name>
    <phone>2059964927</phone>
    <email>jlane@uab.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Lane, RN, BSN</last_name>
      <phone>205-934-1130</phone>
      <email>jlane@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Alan Percy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erica Robertson</last_name>
      <phone>510-428-3885</phone>
      <phone_ext>5458</phone_ext>
      <email>erobertson@mail.cho.org</email>
    </contact>
    <investigator>
      <last_name>Mary Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey Brumback, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Ditslear, MS</last_name>
      <phone>858-246-2288</phone>
      <email>kditslear@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey L Neul, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045-2571</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina VanderVeen</last_name>
      <phone>720-777-5514</phone>
      <email>Gina.VanderVeen@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Tim Benke, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Rohde</last_name>
      <phone>312-942-0079</phone>
      <email>Susan_rohde@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Heydemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Berry-Kravis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colleen Buhrfiend, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Bazin</last_name>
      <phone>617-355-5230</phone>
      <email>Grace.bazin@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lindsay Swanson, BS</last_name>
      <phone>617-355-8994</phone>
      <email>Lindsay.Swanson@childrens.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mustafa Sahin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gillette Children's Specialty Healthcare</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Katoch, CCRC,BS</last_name>
      <phone>651-325-2331</phone>
      <email>rkatoch@gillettechildrens.com</email>
    </contact>
    <investigator>
      <last_name>Arthur Beisang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine and St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Novak</last_name>
      <phone>314-454-4267</phone>
      <email>rettresearch@neuro.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Robin Ryther, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judy Weisenberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14627-0140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>To be named</last_name>
    </contact>
    <investigator>
      <last_name>Alex Paciorkowski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurie Seltzer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Casey Gorman</last_name>
      <phone>267-426-5171</phone>
      <email>GormanC@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Marsh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenwood Genetic Center</name>
      <address>
        <city>Greenwood</city>
        <state>South Carolina</state>
        <zip>29646</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fran Annese, LMSW</last_name>
      <phone>888-442-4363</phone>
      <email>fran@ggc.org</email>
    </contact>
    <investigator>
      <last_name>Mike Friez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steve A Skinner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Thompson</last_name>
      <phone>615-343-4586</phone>
      <email>Nicole.i.thomposon@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Sar Peters, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cary Fu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judy Barrish, BSN, RN</last_name>
      <phone>832-822-7388</phone>
      <email>jobarris@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Daniel G Glaze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernhard Suter, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thuy Dinh, PA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rettsyndrome.org/</url>
    <description>International Rett Syndrome Foundation website</description>
  </link>
  <reference>
    <citation>Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann Neurol. 1983 Oct;14(4):471-9.</citation>
    <PMID>6638958</PMID>
  </reference>
  <reference>
    <citation>Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, Leonard H, Bailey ME, Schanen NC, Zappella M, Renieri A, Huppke P, Percy AK; RettSearch Consortium. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010 Dec;68(6):944-50. doi: 10.1002/ana.22124.</citation>
    <PMID>21154482</PMID>
  </reference>
  <reference>
    <citation>Neul JL, Fang P, Barrish J, Lane J, Caeg EB, Smith EO, Zoghbi H, Percy A, Glaze DG. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology. 2008 Apr 15;70(16):1313-21. doi: 10.1212/01.wnl.0000291011.54508.aa. Epub 2008 Mar 12.</citation>
    <PMID>18337588</PMID>
  </reference>
  <reference>
    <citation>Nan X, Bird A. The biological functions of the methyl-CpG-binding protein MeCP2 and its implication in Rett syndrome. Brain Dev. 2001 Dec;23 Suppl 1:S32-7. Review.</citation>
    <PMID>11738839</PMID>
  </reference>
  <reference>
    <citation>Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999 Oct;23(2):185-8.</citation>
    <PMID>10508514</PMID>
  </reference>
  <reference>
    <citation>Wan M, Lee SS, Zhang X, Houwink-Manville I, Song HR, Amir RE, Budden S, Naidu S, Pereira JL, Lo IF, Zoghbi HY, Schanen NC, Francke U. Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. Am J Hum Genet. 1999 Dec;65(6):1520-9.</citation>
    <PMID>10577905</PMID>
  </reference>
  <reference>
    <citation>Suter B, Treadwell-Deering D, Zoghbi HY, Glaze DG, Neul JL. Brief report: MECP2 mutations in people without Rett syndrome. J Autism Dev Disord. 2014 Mar;44(3):703-11. doi: 10.1007/s10803-013-1902-z.</citation>
    <PMID>23921973</PMID>
  </reference>
  <reference>
    <citation>Laurvick CL, de Klerk N, Bower C, Christodoulou J, Ravine D, Ellaway C, Williamson S, Leonard H. Rett syndrome in Australia: a review of the epidemiology. J Pediatr. 2006 Mar;148(3):347-52.</citation>
    <PMID>16615965</PMID>
  </reference>
  <reference>
    <citation>Kerr AM, Armstrong DD, Prescott RJ, Doyle D, Kearney DL. Rett syndrome: analysis of deaths in the British survey. Eur Child Adolesc Psychiatry. 1997;6 Suppl 1:71-4.</citation>
    <PMID>9452925</PMID>
  </reference>
  <reference>
    <citation>Kirby RS, Lane JB, Childers J, Skinner SA, Annese F, Barrish JO, Glaze DG, Macleod P, Percy AK. Longevity in Rett syndrome: analysis of the North American Database. J Pediatr. 2010 Jan;156(1):135-138.e1. doi: 10.1016/j.jpeds.2009.07.015.</citation>
    <PMID>19772971</PMID>
  </reference>
  <reference>
    <citation>Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science. 2007 Feb 23;315(5815):1143-7. Epub 2007 Feb 8.</citation>
    <PMID>17289941</PMID>
  </reference>
  <reference>
    <citation>Garg SK, Lioy DT, Cheval H, McGann JC, Bissonnette JM, Murtha MJ, Foust KD, Kaspar BK, Bird A, Mandel G. Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. J Neurosci. 2013 Aug 21;33(34):13612-20. doi: 10.1523/JNEUROSCI.1854-13.2013.</citation>
    <PMID>23966684</PMID>
  </reference>
  <reference>
    <citation>Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron. 2006 Feb 2;49(3):341-8.</citation>
    <PMID>16446138</PMID>
  </reference>
  <reference>
    <citation>Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, Flannery R, Jaenisch R, Sur M. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):2029-34. doi: 10.1073/pnas.0812394106.</citation>
    <PMID>19208815</PMID>
  </reference>
  <reference>
    <citation>Archer H, Evans J, Leonard H, Colvin L, Ravine D, Christodoulou J, Williamson S, Charman T, Bailey ME, Sampson J, de Klerk N, Clarke A. Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation. J Med Genet. 2007 Feb;44(2):148-52. Epub 2006 Aug 11.</citation>
    <PMID>16905679</PMID>
  </reference>
  <reference>
    <citation>Leonard H, Bower C. Is the girl with Rett syndrome normal at birth? Dev Med Child Neurol. 1998 Feb;40(2):115-21.</citation>
    <PMID>9489500</PMID>
  </reference>
  <reference>
    <citation>Kerr AM. Early clinical signs in the Rett disorder. Neuropediatrics. 1995 Apr;26(2):67-71.</citation>
    <PMID>7566455</PMID>
  </reference>
  <reference>
    <citation>Einspieler C, Kerr AM, Prechtl HF. Abnormal general movements in girls with Rett disorder: the first four months of life. Brain Dev. 2005 Nov;27 Suppl 1:S8-S13. Epub 2005 Sep 21.</citation>
    <PMID>16182501</PMID>
  </reference>
  <reference>
    <citation>Einspieler C, Kerr AM, Prechtl HF. Is the early development of girls with Rett disorder really normal? Pediatr Res. 2005 May;57(5 Pt 1):696-700. Epub 2005 Feb 17.</citation>
    <PMID>15718369</PMID>
  </reference>
  <reference>
    <citation>Downs J, Bebbington A, Kaufmann WE, Leonard H. Longitudinal hand function in Rett syndrome. J Child Neurol. 2011 Mar;26(3):334-40. doi: 10.1177/0883073810381920. Epub 2010 Oct 4.</citation>
    <PMID>20921565</PMID>
  </reference>
  <reference>
    <citation>Downs JA, Bebbington A, Jacoby P, Msall ME, McIlroy O, Fyfe S, Bahi-Buisson N, Kaufmann WE, Leonard H. Gross motor profile in rett syndrome as determined by video analysis. Neuropediatrics. 2008 Aug;39(4):205-10. doi: 10.1055/s-0028-1104575. Epub 2009 Jan 22.</citation>
    <PMID>19165708</PMID>
  </reference>
  <reference>
    <citation>Neul, J.L. Rett Syndrome and MECP2-Related Disorders. in Autism Spectrum Disorders (eds. Amaral, D., Geschwind, D. &amp; Dawson, G.) 776-800 (Oxford University Press, New York, 2011).</citation>
  </reference>
  <reference>
    <citation>Nectoux J, Bahi-Buisson N, Guellec I, Coste J, De Roux N, Rosas H, Tardieu M, Chelly J, Bienvenu T. The p.Val66Met polymorphism in the BDNF gene protects against early seizures in Rett syndrome. Neurology. 2008 May 27;70(22 Pt 2):2145-51. doi: 10.1212/01.wnl.0000304086.75913.b2. Epub 2008 Apr 23.</citation>
    <PMID>18434641</PMID>
  </reference>
  <reference>
    <citation>Zeev BB, Bebbington A, Ho G, Leonard H, de Klerk N, Gak E, Vecsler M, Christodoulou J. The common BDNF polymorphism may be a modifier of disease severity in Rett syndrome. Neurology. 2009 Apr 7;72(14):1242-7. doi: 10.1212/01.wnl.0000345664.72220.6a. Erratum in: Neurology. 2009 Jul 14;73(2):161. Vecksler, M [corrected to Vecsler, M].</citation>
    <PMID>19349604</PMID>
  </reference>
  <reference>
    <citation>Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003 Jan 24;112(2):257-69.</citation>
    <PMID>12553913</PMID>
  </reference>
  <reference>
    <citation>Buchovecky CM, Turley SD, Brown HM, Kyle SM, McDonald JG, Liu B, Pieper AA, Huang W, Katz DM, Russell DW, Shendure J, Justice MJ. A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nat Genet. 2013 Sep;45(9):1013-20. doi: 10.1038/ng.2714. Epub 2013 Jul 28.</citation>
    <PMID>23892605</PMID>
  </reference>
  <reference>
    <citation>Bebbington A, Anderson A, Ravine D, Fyfe S, Pineda M, de Klerk N, Ben-Zeev B, Yatawara N, Percy A, Kaufmann WE, Leonard H. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. Neurology. 2008 Mar 11;70(11):868-75. doi: 10.1212/01.wnl.0000304752.50773.ec.</citation>
    <PMID>18332345</PMID>
  </reference>
  <reference>
    <citation>Ramocki MB, Peters SU, Tavyev YJ, Zhang F, Carvalho CM, Schaaf CP, Richman R, Fang P, Glaze DG, Lupski JR, Zoghbi HY. Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome. Ann Neurol. 2009 Dec;66(6):771-82. doi: 10.1002/ana.21715.</citation>
    <PMID>20035514</PMID>
  </reference>
  <reference>
    <citation>Peters SU, Hundley RJ, Wilson AK, Carvalho CM, Lupski JR, Ramocki MB. Brief report: regression timing and associated features in MECP2 duplication syndrome. J Autism Dev Disord. 2013 Oct;43(10):2484-90. doi: 10.1007/s10803-013-1796-9.</citation>
    <PMID>23456562</PMID>
  </reference>
  <reference>
    <citation>Friez MJ, Jones JR, Clarkson K, Lubs H, Abuelo D, Bier JA, Pai S, Simensen R, Williams C, Giampietro PF, Schwartz CE, Stevenson RE. Recurrent infections, hypotonia, and mental retardation caused by duplication of MECP2 and adjacent region in Xq28. Pediatrics. 2006 Dec;118(6):e1687-95. Epub 2006 Nov 6.</citation>
    <PMID>17088400</PMID>
  </reference>
  <reference>
    <citation>Van Esch H, Bauters M, Ignatius J, Jansen M, Raynaud M, Hollanders K, Lugtenberg D, Bienvenu T, Jensen LR, Gecz J, Moraine C, Marynen P, Fryns JP, Froyen G. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet. 2005 Sep;77(3):442-53. Epub 2005 Jul 29.</citation>
    <PMID>16080119</PMID>
  </reference>
  <reference>
    <citation>Ramocki MB, Tavyev YJ, Peters SU. The MECP2 duplication syndrome. Am J Med Genet A. 2010 May;152A(5):1079-88. doi: 10.1002/ajmg.a.33184. Review.</citation>
    <PMID>20425814</PMID>
  </reference>
  <reference>
    <citation>Van Esch H. MECP2 Duplication Syndrome. Mol Syndromol. 2012 Apr;2(3-5):128-136. Epub 2011 Jul 5.</citation>
    <PMID>22679399</PMID>
  </reference>
  <reference>
    <citation>Carvalho CM, Ramocki MB, Pehlivan D, Franco LM, Gonzaga-Jauregui C, Fang P, McCall A, Pivnick EK, Hines-Dowell S, Seaver LH, Friehling L, Lee S, Smith R, Del Gaudio D, Withers M, Liu P, Cheung SW, Belmont JW, Zoghbi HY, Hastings PJ, Lupski JR. Inverted genomic segments and complex triplication rearrangements are mediated by inverted repeats in the human genome. Nat Genet. 2011 Oct 2;43(11):1074-81. doi: 10.1038/ng.944.</citation>
    <PMID>21964572</PMID>
  </reference>
  <reference>
    <citation>Yang T, Ramocki MB, Neul JL, Lu W, Roberts L, Knight J, Ward CS, Zoghbi HY, Kheradmand F, Corry DB. Overexpression of methyl-CpG binding protein 2 impairs T(H)1 responses. Sci Transl Med. 2012 Dec 5;4(163):163ra158. doi: 10.1126/scitranslmed.3004430.</citation>
    <PMID>23220634</PMID>
  </reference>
  <reference>
    <citation>Na ES, Nelson ED, Adachi M, Autry AE, Mahgoub MA, Kavalali ET, Monteggia LM. A mouse model for MeCP2 duplication syndrome: MeCP2 overexpression impairs learning and memory and synaptic transmission. J Neurosci. 2012 Feb 29;32(9):3109-17. doi: 10.1523/JNEUROSCI.6000-11.2012.</citation>
    <PMID>22378884</PMID>
  </reference>
  <reference>
    <citation>Na ES, Nelson ED, Kavalali ET, Monteggia LM. The impact of MeCP2 loss- or gain-of-function on synaptic plasticity. Neuropsychopharmacology. 2013 Jan;38(1):212-9. doi: 10.1038/npp.2012.116. Epub 2012 Jul 11. Review.</citation>
    <PMID>22781840</PMID>
  </reference>
  <reference>
    <citation>Ariani F, Mari F, Pescucci C, Longo I, Bruttini M, Meloni I, Hayek G, Rocchi R, Zappella M, Renieri A. Real-time quantitative PCR as a routine method for screening large rearrangements in Rett syndrome: Report of one case of MECP2 deletion and one case of MECP2 duplication. Hum Mutat. 2004 Aug;24(2):172-7.</citation>
    <PMID>15241799</PMID>
  </reference>
  <reference>
    <citation>Meins M, Lehmann J, Gerresheim F, Herchenbach J, Hagedorn M, Hameister K, Epplen JT. Submicroscopic duplication in Xq28 causes increased expression of the MECP2 gene in a boy with severe mental retardation and features of Rett syndrome. J Med Genet. 2005 Feb;42(2):e12.</citation>
    <PMID>15689435</PMID>
  </reference>
  <reference>
    <citation>Grasshoff U, Bonin M, Goehring I, Ekici A, Dufke A, Cremer K, Wagner N, Rossier E, Jauch A, Walter M, Bauer C, Bauer P, Horber K, Beck-Woedl S, Wieczorek D. De novo MECP2 duplication in two females with random X-inactivation and moderate mental retardation. Eur J Hum Genet. 2011 May;19(5):507-12. doi: 10.1038/ejhg.2010.226. Epub 2011 Feb 16.</citation>
    <PMID>21326285</PMID>
  </reference>
  <reference>
    <citation>del Gaudio D, Fang P, Scaglia F, Ward PA, Craigen WJ, Glaze DG, Neul JL, Patel A, Lee JA, Irons M, Berry SA, Pursley AA, Grebe TA, Freedenberg D, Martin RA, Hsich GE, Khera JR, Friedman NR, Zoghbi HY, Eng CM, Lupski JR, Beaudet AL, Cheung SW, Roa BB. Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males. Genet Med. 2006 Dec;8(12):784-92.</citation>
    <PMID>17172942</PMID>
  </reference>
  <reference>
    <citation>Carvalho CM, Zhang F, Liu P, Patel A, Sahoo T, Bacino CA, Shaw C, Peacock S, Pursley A, Tavyev YJ, Ramocki MB, Nawara M, Obersztyn E, Vianna-Morgante AM, Stankiewicz P, Zoghbi HY, Cheung SW, Lupski JR. Complex rearrangements in patients with duplications of MECP2 can occur by fork stalling and template switching. Hum Mol Genet. 2009 Jun 15;18(12):2188-203. doi: 10.1093/hmg/ddp151. Epub 2009 Mar 26.</citation>
    <PMID>19324899</PMID>
  </reference>
  <reference>
    <citation>Reardon W, Donoghue V, Murphy AM, King MD, Mayne PD, Horn N, Birk Møller L. Progressive cerebellar degenerative changes in the severe mental retardation syndrome caused by duplication of MECP2 and adjacent loci on Xq28. Eur J Pediatr. 2010 Aug;169(8):941-9. doi: 10.1007/s00431-010-1144-4. Epub 2010 Feb 23.</citation>
    <PMID>20177701</PMID>
  </reference>
  <reference>
    <citation>Honda S, Hayashi S, Nakane T, Imoto I, Kurosawa K, Mizuno S, Okamoto N, Kato M, Yoshihashi H, Kubota T, Nakagawa E, Goto Y, Inazawa J. The incidence of hypoplasia of the corpus callosum in patients with dup (X)(q28) involving MECP2 is associated with the location of distal breakpoints. Am J Med Genet A. 2012 Jun;158A(6):1292-303. doi: 10.1002/ajmg.a.35321. Epub 2012 Apr 23.</citation>
    <PMID>22528406</PMID>
  </reference>
  <reference>
    <citation>Vignoli A, Borgatti R, Peron A, Zucca C, Ballarati L, Bonaglia C, Bellini M, Giordano L, Romaniello R, Bedeschi MF, Epifanio R, Russo S, Caselli R, Giardino D, Darra F, La Briola F, Banderali G, Canevini MP. Electroclinical pattern in MECP2 duplication syndrome: eight new reported cases and review of literature. Epilepsia. 2012 Jul;53(7):1146-55. doi: 10.1111/j.1528-1167.2012.03501.x. Epub 2012 May 11. Review.</citation>
    <PMID>22578097</PMID>
  </reference>
  <reference>
    <citation>Lupski JR. Genomic disorders ten years on. Genome Med. 2009 Apr 24;1(4):42. doi: 10.1186/gm42.</citation>
    <PMID>19439022</PMID>
  </reference>
  <reference>
    <citation>Hanashima C, Fernandes M, Hebert JM, Fishell G. The role of Foxg1 and dorsal midline signaling in the generation of Cajal-Retzius subtypes. J Neurosci. 2007 Oct 10;27(41):11103-11.</citation>
    <PMID>17928452</PMID>
  </reference>
  <reference>
    <citation>Brancaccio M, Pivetta C, Granzotto M, Filippis C, Mallamaci A. Emx2 and Foxg1 inhibit gliogenesis and promote neuronogenesis. Stem Cells. 2010 Jul;28(7):1206-18. doi: 10.1002/stem.443.</citation>
    <PMID>20506244</PMID>
  </reference>
  <reference>
    <citation>Bahi-Buisson N, Villeneuve N, Caietta E, Jacquette A, Maurey H, Matthijs G, Van Esch H, Delahaye A, Moncla A, Milh M, Zufferey F, Diebold B, Bienvenu T. Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships. Am J Med Genet A. 2012 Jul;158A(7):1612-9. doi: 10.1002/ajmg.a.35401. Epub 2012 Jun 7.</citation>
    <PMID>22678952</PMID>
  </reference>
  <reference>
    <citation>Nemos C, Lambert L, Giuliano F, Doray B, Roubertie A, Goldenberg A, Delobel B, Layet V, N'guyen MA, Saunier A, Verneau F, Jonveaux P, Philippe C. Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature. Clin Genet. 2009 Oct;76(4):357-71. doi: 10.1111/j.1399-0004.2009.01194.x. Review.</citation>
    <PMID>19793311</PMID>
  </reference>
  <reference>
    <citation>Brunetti-Pierri N, Paciorkowski AR, Ciccone R, Della Mina E, Bonaglia MC, Borgatti R, Schaaf CP, Sutton VR, Xia Z, Jelluma N, Ruivenkamp C, Bertrand M, de Ravel TJ, Jayakar P, Belli S, Rocchetti K, Pantaleoni C, D'Arrigo S, Hughes J, Cheung SW, Zuffardi O, Stankiewicz P. Duplications of FOXG1 in 14q12 are associated with developmental epilepsy, mental retardation, and severe speech impairment. Eur J Hum Genet. 2011 Jan;19(1):102-7. doi: 10.1038/ejhg.2010.142. Epub 2010 Aug 25.</citation>
    <PMID>20736978</PMID>
  </reference>
  <reference>
    <citation>Wang IT, Allen M, Goffin D, Zhu X, Fairless AH, Brodkin ES, Siegel SJ, Marsh ED, Blendy JA, Zhou Z. Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21516-21. doi: 10.1073/pnas.1216988110. Epub 2012 Dec 10.</citation>
    <PMID>23236174</PMID>
  </reference>
  <reference>
    <citation>Huppke P, Held M, Laccone F, Hanefeld F. The spectrum of phenotypes in females with Rett Syndrome. Brain Dev. 2003 Aug;25(5):346-51.</citation>
    <PMID>12850514</PMID>
  </reference>
  <reference>
    <citation>Rajaei S, Erlandson A, Kyllerman M, Albage M, Lundstrom I, Karrstedt EL, Hagberg B. Early infantile onset ''congenital'' Rett syndrome variants: Swedish experience through four decades and mutation analysis. J Child Neurol. 2011 Jan;26(1):65-71. doi: 10.1177/0883073810374125.</citation>
    <PMID>21212452</PMID>
  </reference>
  <reference>
    <citation>Nectoux J, Fichou Y, Cagnard N, Bahi-Buisson N, Nusbaum P, Letourneur F, Chelly J, Bienvenu T. Cell cloning-based transcriptome analysis in cyclin-dependent kinase-like 5 mutation patients with severe epileptic encephalopathy. J Mol Med (Berl). 2011 Feb;89(2):193-202. doi: 10.1007/s00109-010-0699-x. Epub 2010 Nov 24.</citation>
    <PMID>21107515</PMID>
  </reference>
  <reference>
    <citation>Ricciardi S, Kilstrup-Nielsen C, Bienvenu T, Jacquette A, Landsberger N, Broccoli V. CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery. Hum Mol Genet. 2009 Dec 1;18(23):4590-602. doi: 10.1093/hmg/ddp426. Epub 2009 Sep 9.</citation>
    <PMID>19740913</PMID>
  </reference>
  <reference>
    <citation>Weaving LS, Christodoulou J, Williamson SL, Friend KL, McKenzie OL, Archer H, Evans J, Clarke A, Pelka GJ, Tam PP, Watson C, Lahooti H, Ellaway CJ, Bennetts B, Leonard H, Gécz J. Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am J Hum Genet. 2004 Dec;75(6):1079-93. Epub 2004 Oct 18.</citation>
    <PMID>15492925</PMID>
  </reference>
  <reference>
    <citation>Bahi-Buisson N, Kaminska A, Boddaert N, Rio M, Afenjar A, Gérard M, Giuliano F, Motte J, Héron D, Morel MA, Plouin P, Richelme C, des Portes V, Dulac O, Philippe C, Chiron C, Nabbout R, Bienvenu T. The three stages of epilepsy in patients with CDKL5 mutations. Epilepsia. 2008 Jun;49(6):1027-37. doi: 10.1111/j.1528-1167.2007.01520.x. Epub 2008 Feb 7.</citation>
    <PMID>18266744</PMID>
  </reference>
  <reference>
    <citation>Bahi-Buisson N, Nectoux J, Rosas-Vargas H, Milh M, Boddaert N, Girard B, Cances C, Ville D, Afenjar A, Rio M, Héron D, N'guyen Morel MA, Arzimanoglou A, Philippe C, Jonveaux P, Chelly J, Bienvenu T. Key clinical features to identify girls with CDKL5 mutations. Brain. 2008 Oct;131(Pt 10):2647-61. doi: 10.1093/brain/awn197. Epub 2008 Sep 12.</citation>
    <PMID>18790821</PMID>
  </reference>
  <reference>
    <citation>Fehr S, Wilson M, Downs J, Williams S, Murgia A, Sartori S, Vecchi M, Ho G, Polli R, Psoni S, Bao X, de Klerk N, Leonard H, Christodoulou J. The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. Eur J Hum Genet. 2013 Mar;21(3):266-73. doi: 10.1038/ejhg.2012.156. Epub 2012 Aug 8.</citation>
    <PMID>22872100</PMID>
  </reference>
  <reference>
    <citation>Melani F, Mei D, Pisano T, Savasta S, Franzoni E, Ferrari AR, Marini C, Guerrini R. CDKL5 gene-related epileptic encephalopathy: electroclinical findings in the first year of life. Dev Med Child Neurol. 2011 Apr;53(4):354-60. doi: 10.1111/j.1469-8749.2010.03889.x. Epub 2011 Feb 11.</citation>
    <PMID>21309761</PMID>
  </reference>
  <reference>
    <citation>Elia M, Falco M, Ferri R, Spalletta A, Bottitta M, Calabrese G, Carotenuto M, Musumeci SA, Lo Giudice M, Fichera M. CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy. Neurology. 2008 Sep 23;71(13):997-9. doi: 10.1212/01.wnl.0000326592.37105.88.</citation>
    <PMID>18809835</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2016</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Alan Percy</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Rett Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing agreement approved by the Rare Disease Clinical Research Network will be employed.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

